| Autor: |
Mijanović O; Dia-M, LCC, 7 b.3 Magadanskaya Str., 129345 Moscow, Russia.; The Human Pathology Department, Sechenov First Moscow State University, 119991 Moscow, Russia., Jakovleva A; HoxLife Science GmbH, Gutleutstraße 169-171, 60327 Frankfurt am Main, Germany., Branković A; Department of Forensics Engineering, University of Criminal Investigation and Police Studies, Cara Dusana 196, 11000 Belgrade, Serbia., Zdravkova K; AD Alkaloid Skopje, Boulevar Alexander the Great 12, 1000 Skopje, North Macedonia., Pualic M; Institute Cardiovascular Diseases Dedinje, Heroja Milana Tepica 1, 11000 Belgrade, Serbia., Belozerskaya TA; Bach Institute of Biochemistry, Research Center of Biotechnology, Russian Academy of Sciences, 119071 Moscow, Russia., Nikitkina AI; ArhiMed Clinique for New Medical Technologies, Vavilova St. 68/2, 119261 Moscow, Russia., Parodi A; Scientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, Russia.; Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia., Zamyatnin AA Jr; Scientific Center for Translation Medicine, Sirius University of Science and Technology, 354340 Sochi, Russia.; Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991 Moscow, Russia.; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.; Faculty of Health and Medical Sciences, University of Surrey, Guildford GU2 7X, UK. |
| Abstrakt: |
Cathepsin K (CatK) is a part of the family of cysteine proteases involved in many important processes, including the degradation activity of collagen 1 and elastin in bone resorption. Changes in levels of CatK are associated with various pathological conditions, primarily related to bone and cartilage degradation, such as pycnodysostosis (associated with CatK deficiency), osteoporosis, and osteoarthritis (associated with CatK overexpression). Recently, the increased secretion of CatK is being highly correlated to vascular inflammation, hypersensitivity pneumonitis, Wegener granulomatosis, berylliosis, tuberculosis, as well as with tumor progression. Due to the wide spectrum of diseases in which CatK is involved, the design and validation of active site-specific inhibitors has been a subject of keen interest in pharmaceutical companies in recent decades. In this review, we summarized the molecular background of CatK and its involvement in various diseases, as well as its clinical significance for diagnosis and therapy. |
